ENTRY       D11400                      Drug
NAME        Abrocitinib (JAN/USAN);
            Cibinqo (TN)
PRODUCT     CIBINQO (Pfizer Laboratories Div Pfizer)
            CIBINQO (U.S. Pharmaceuticals)
FORMULA     C14H21N5O2S
EXACT_MASS  323.1416
MOL_WEIGHT  323.4138
CLASS       Anti-inflammatory
             DG01985  Disease modifying anti-rheumatic drug (DMARD)
              DG02020  JAK inhibitor
            Dermatological agent
             DG03243  Atopic dermatitis agent
            Metabolizing enzyme substrate
             DG01642  CYP2C9 substrate
             DG01639  CYP2C19 substrate
REMARK      Therapeutic category: 4490
            ATC code: D11AH08
            Product: D11400<JP/US>
EFFICACY    Anti-inflammatory, Janus kinase (JAK) inhibitor
  DISEASE   Atopic dermatitis [DS:H01358]
COMMENT     Treatment of atopic dermatitis
TARGET      JAK1 [HSA:3716] [KO:K11217]
  PATHWAY   hsa04630(3716)  JAK-STAT signaling pathway
            hsa04658(3716)  Th1 and Th2 cell differentiation
METABOLISM  Enzyme: CYP2C19 [HSA:1557], CYP2C9 [HSA:1559]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             D DERMATOLOGICALS
              D11 OTHER DERMATOLOGICAL PREPARATIONS
               D11A OTHER DERMATOLOGICAL PREPARATIONS
                D11AH Agents for dermatitis, excluding corticosteroids
                 D11AH08 Abrocitinib
                  D11400  Abrocitinib (JAN/USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunological Agents, Other
               JAK Inhibitors
                Abrocitinib
                 D11400  Abrocitinib (JAN/USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              44  Allergic agents
               449  Miscellaneous
                4490  Miscellaneous
                 D11400  Abrocitinib (JAN/USAN)
            Drug groups [BR:br08330]
             Anti-inflammatory
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               DG02020  JAK inhibitor
                D11400  Abrocitinib
             Dermatological agent
              DG03243  Atopic dermatitis agent
               D11400  Abrocitinib
             Metabolizing enzyme substrate
              DG01642  CYP2C9 substrate
               D11400  Abrocitinib
              DG01639  CYP2C19 substrate
               D11400  Abrocitinib
            Drug classes [BR:br08332]
             Immunological agent
              DG02020  JAK inhibitor
               D11400  Abrocitinib
             Antirheumatic agent
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               D11400  Abrocitinib
             Dermatological agent
              DG03243  Atopic dermatitis agent
               D11400  Abrocitinib
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Non-receptor tyrosine kinases
               JAK family
                JAK1
                 D11400  Abrocitinib (JAN/USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11400
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11400
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11400
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11400
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D11400
            Pharmacogenomic biomarkers [br08341.html]
             Polymorphisms and mutations affecting drug response
              D11400
DBLINKS     CAS: 1622902-68-4
            PubChem: 384585378
            PDB-CCD: D7D
ATOM        22
            1   C8y C    12.9500  -16.9400
            2   C8y C    12.9500  -18.3400
            3   N5x N    11.7600  -19.0400
            4   C8x C    10.5000  -18.3400
            5   N5x N    10.5000  -16.9400
            6   C8y C    11.7600  -16.2400
            7   N4x N    14.2815  -18.7726
            8   C8x C    15.1044  -17.6400
            9   C8x C    14.2815  -16.5074
            10  N1c N    11.7772  -14.8401
            11  C1a C    12.9851  -14.1624
            12  C1y C    10.5608  -14.1176
            13  C1x C    10.2211  -12.7842
            14  C1y C     8.8877  -13.1238
            15  C1x C     9.2273  -14.4573
            16  N1b N     7.6710  -12.4015
            17  S4a S     6.4772  -13.0717
            18  C1b C     5.3056  -12.3762
            19  O3c O     5.7772  -14.2841
            20  O3c O     7.1772  -14.2841
            21  C1b C     4.0900  -13.0587
            22  C1a C     2.8784  -12.3392
BOND        24
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     2   7 1
            8     7   8 1
            9     8   9 2
            10    1   9 1
            11    6  10 1
            12   10  11 1
            13   12  10 1 #Up
            14   12  13 1
            15   13  14 1
            16   14  15 1
            17   12  15 1
            18   14  16 1 #Up
            19   16  17 1
            20   17  18 1
            21   17  19 2
            22   17  20 2
            23   18  21 1
            24   21  22 1
///
